List of Excipients in Branded Drug SUMATRIPTAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	SUMATRIPTAN	sumatriptan	0781-6524	POTASSIUM PHOSPHATE, MONOBASIC
Sandoz Inc	SUMATRIPTAN	sumatriptan	0781-6524	SODIUM HYDROXIDE
Sandoz Inc	SUMATRIPTAN	sumatriptan	0781-6524	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
Sandoz Inc	SUMATRIPTAN	sumatriptan	0781-6524	SULFURIC ACID
Sandoz Inc	SUMATRIPTAN	sumatriptan	0781-6524	WATER
Physicians Total Care Inc	SUMATRIPTAN	sumatriptan	54868-6052	POTASSIUM PHOSPHATE, MONOBASIC
Physicians Total Care Inc	SUMATRIPTAN	sumatriptan	54868-6052	SODIUM HYDROXIDE

Generic Drugs Containing SUMATRIPTAN

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	sumatriptan succinate	0093-2013	SODIUM CHLORIDE
Teva Pharmaceuticals USA Inc	sumatriptan succinate	0093-2013	WATER
Hikma Pharmaceuticals USA Inc	sumatriptan	0143-9638	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	sumatriptan	0143-9638	WATER
Lannett Company Inc	sumatriptan	0527-1818	POTASSIUM PHOSPHATE, MONOBASIC
Lannett Company Inc	sumatriptan	0527-1818	SODIUM HYDROXIDE
Lannett Company Inc	sumatriptan	0527-1818	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

What are the Most Frequently-Used Excipients in SUMATRIPTAN?

# Of NDCs	Excipient
17	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
6	ANHYDROUS LACTOSE
4	BENZALKONIUM CHLORIDE
29	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
53	CELLULOSE, MICROCRYSTALLINE
1	CI 77492
1	CI 77891

Sumatriptan Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 8, 2026

Sumatriptan is a mature, genericized migraine medicine with limited value in the active pharmaceutical ingredient and substantial opportunity in delivery systems, excipient selection, device integration, and patient adherence. The strongest commercial positions are differentiated nasal, orally disintegrating, rapid-release, pediatric, and combination products rather than conventional immediate-release tablets.

The principal formulation constraints are unpleasant taste, variable oral absorption during migraine attacks, low aqueous solubility of the free base, local nasal tolerability, injection-site comfort, and the need for rapid systemic exposure. Excipient strategy can address those issues, but patent protection generally depends on the complete formulation, process, device, or method of use rather than on an excipient alone.

What is sumatriptan and which dosage forms are commercially available?

Sumatriptan is a selective 5-HT1B/1D receptor agonist approved for the acute treatment of migraine, with or without aura, and cluster headache in selected formulations. The marketed chemical form is commonly sumatriptan succinate, although products differ in route, concentration, device, and excipient system.

Dosage form	Representative product or category	Key commercial attribute	Primary excipient challenge
Immediate-release tablet	Generic sumatriptan tablets, formerly Imitrex	Lowest-cost, high-volume route	Delayed or variable absorption during nausea and gastric stasis
Subcutaneous injection	Imitrex injection and authorized/generic presentations	Fastest established systemic delivery	Injection comfort, pH, tonicity, preservative strategy
Nasal spray	Imitrex nasal spray, generic sprays, Tosymra	Avoids swallowing and may improve speed	Nasal irritation, taste, plume or spray deposition
Nasal powder	Onzetra Xsail	Breath-powered delivery and differentiated device	Powder flow, moisture control, dose uniformity
Transdermal iontophoretic system	Zecuity, withdrawn from the U.S. market	Non-oral, non-injectable delivery	Skin reactions, device complexity, manufacturing cost
Oral film or ODT concept	Development and generic opportunity	Potentially useful when swallowing is difficult	Taste masking, rapid disintegration, dose loading

The original Imitrex products were developed by Glaxo Wellcome and later marketed by GlaxoSmithKline. Sumatriptan tablets, nasal spray, and injection were approved in the 1990s. Generic competition followed after expiration of the principal U.S. exclusivity and patent barriers.

When did sumatriptan lose exclusivity?

Sumatriptan lost its core U.S. market exclusivity many years ago. The principal opportunities are now product-level improvements, not compound-level exclusivity.

Core compound and Orange Book status

The original sumatriptan compound and early product patents expired before the current generic market was established. FDA Orange Book records identify approved generic sumatriptan products across tablets, nasal spray, and injection categories. Active listings, if any, are product-specific and should be evaluated by dosage form and applicant rather than by the molecule as a whole. The Orange Book does not create exclusivity for every excipient combination or every commercial presentation. [1]

Historically, the key milestones were:

• FDA approval of Imitrex tablets in 1992.
• FDA approval of Imitrex injection in 1996.
• FDA approval of Imitrex nasal spray in 1997.
• U.S. generic tablet launches after expiration of the principal listed patents and associated exclusivity.
• Later product approvals based on new delivery systems, including transdermal and breath-powered nasal delivery.

Sumatriptan therefore has no meaningful biosimilar barrier. It is a small-molecule drug, and follow-on products proceed through abbreviated new drug application, 505(b)(2), or conventional new drug application pathways rather than the biosimilar pathway.

What patents protect sumatriptan formulations?

The strongest historical patent positions covered the active compound, therapeutic use, pharmaceutical compositions, nasal delivery, iontophoretic transdermal delivery, and device-enabled administration. New commercial protection must generally be built around a specific formulation or delivery system.

Patent categories relevant to sumatriptan

Patent category	Commercial relevance	Current strategic value
Compound patents	Protected sumatriptan and related chemical matter	Largely expired
Salt and solid-state patents	Covered forms such as succinate and crystallinity	Limited unless a novel form improves manufacturability
Tablet formulation patents	Covered compression, dissolution, stability, or excipient systems	Moderate for differentiated generic or 505(b)(2) products
Nasal formulation patents	Covered concentration, pH, osmolality, preservatives, and deposition	High when linked to improved tolerability or exposure
Powder formulation patents	Covered particle size, carrier, moisture, and device interaction	High for device-led products
Transdermal patents	Covered iontophoresis, electrodes, and patch architecture	Historical importance; commercial viability was poor
Method-of-use patents	Covered acute migraine or cluster headache use, dosing, or patient subgroups	Narrow and vulnerable to invalidity or design-around
Device patents	Covered actuators, breath-powered delivery, dose counters, and packaging	Often more durable than core drug patents
Manufacturing patents	Covered blending, micronization, sterilization, filling, or assembly	Relevant where process reproducibility is difficult

A formulation patent must demonstrate more than the presence of a conventional excipient. Lactose, mannitol, microcrystalline cellulose, povidone, sodium chloride, buffers, preservatives, and surfactants are generally established pharmaceutical materials. Protection is stronger when the patent claims a defined concentration range, particle-size distribution, pH window, dissolution profile, device interaction, stability advantage, or clinically meaningful pharmacokinetic result.

What excipients are used in sumatriptan products?

Excipients vary by manufacturer and dosage form. Exact composition should be confirmed against the applicable FDA label and product-specific regulatory filing.

Tablet excipient strategy

Immediate-release sumatriptan tablets commonly use excipients from the following classes:

• Diluent or filler, such as microcrystalline cellulose, lactose, or calcium phosphate.
• Disintegrant, such as croscarmellose sodium, crospovidone, or sodium starch glycolate.
• Binder, such as povidone or hypromellose.
• Glidant, such as colloidal silicon dioxide.
• Lubricant, such as magnesium stearate.
• Film-coating materials, including hypromellose, polyethylene glycol, talc, and colorants.

The tablet formulation objective is rapid disintegration and dissolution rather than extended release. Sumatriptan has relatively low oral bioavailability, approximately 15%, because of first-pass metabolism. A tablet excipient system that produces faster dissolution may improve early exposure, but it cannot eliminate gastric emptying delays or first-pass metabolism. [2]

A commercial opportunity exists for:

• Low-mass tablets with rapid disintegration.
• Taste-masked orally disintegrating tablets.
• Tablets designed for patients with nausea or dysphagia.
• Packaging optimized for migraine portability and moisture protection.
• Lower-cost products without colorants or unnecessary excipients.

Nasal spray excipient strategy

Nasal products commonly require:

• Aqueous vehicle.
• pH-adjusting buffer.
• Tonicity agent, such as sodium chloride.
• Preservative in multidose formats.
• Surfactant or wetting agent where needed.
• Solubilizer or cosolvent where needed.
• Antioxidant or chelating agent if degradation pathways justify inclusion.

Nasal sumatriptan formulations must balance solubility against local tolerability. A low-pH solution may support chemical stability or solubility but can increase burning, irritation, and undesirable throat taste. Excessive osmolality can also reduce tolerability.

The best formulation work focuses on deposition and retention rather than simply increasing drug concentration. Mucoadhesive polymers can increase residence time, but they may slow diffusion, alter spray performance, or produce a less acceptable sensation. Viscosity must remain compatible with the pump, actuator, and dose uniformity requirements.

Preservative-free multidose systems may create a commercial distinction, but they require validated container-closure integrity and microbial control. Unit-dose packaging can eliminate preservative exposure but increases packaging cost and waste.

Nasal powder excipient strategy

Powder-based delivery has a different technical profile. Relevant excipients include:

• Lactose or mannitol carriers.
• Amino acids or dispersibility modifiers.
• Flow aids.
• Moisture-control agents.
• Surface-modified particles.
• Stabilizers for micronized drug.

The central development variables are aerodynamic particle size, emitted dose, deaggregation, moisture uptake, and device resistance. A powder that performs well in a capsule or laboratory inhaler may fail in a breath-powered nasal device because the patient-generated airflow is variable.

A patent position can be stronger where the claims connect:

1. A defined particle-size distribution.
2. A specified carrier or surface treatment.
3. A defined emitted-dose or deposition profile.
4. A particular breath-powered device.
5. A clinical benefit such as faster relief or reduced swallowing.

Onzetra Xsail illustrates this strategy. The product combined sumatriptan powder with a breath-powered nasal delivery system and was approved through a differentiated product pathway. [3]

Injection excipient strategy

Subcutaneous sumatriptan products require an aqueous sterile formulation with control of:

• pH.
• Osmolality.
• Chemical stability.
• Particulate matter.
• Container compatibility.
• Injection volume.
• Preservative exposure, where applicable.

For injection products, excipient innovation has less commercial room because the formulation must remain simple, sterile, and well tolerated. Opportunities include lower-volume dosing, autoinjector compatibility, reduced injection pain, preservative-free packaging, and improved stability in cartridge or pen systems.

Local tolerability may be influenced by pH, ionic strength, osmolality, buffer capacity, and injection volume. Claims based on a lower-irritation formulation require comparative clinical or human-factors evidence, not only laboratory pH data.

What formulations are protected by sumatriptan product patents?

Product-level protection is most credible for formulations that solve a recognized limitation of conventional sumatriptan.

High-value formulation targets

Rapid-onset nasal formulations

A formulation that improves nasal absorption while reducing burning and taste may support a 505(b)(2) strategy or a differentiated generic strategy. Useful claim elements include:

• Drug concentration.
• Buffer composition.
• pH range.
• Osmolality range.
• Preservative-free architecture.
• Spray droplet-size distribution.
• Dose volume.
• Nasal deposition.
• Pharmacokinetic profile.

Taste-masked oral products

Taste masking has commercial value because sumatriptan can be unpleasant when dissolved or dispersed in the mouth. Possible technologies include polymer coating, ion-exchange resins, lipid barriers, cyclodextrin complexes, and multiparticulate systems.

The patent must show adequate taste reduction without compromising rapid release. A conventional orally disintegrating tablet with a standard sweetener and flavor system is unlikely to create a durable exclusionary position without a specific technical effect.

Breath-powered powder products

Powder products can protect the device-formulation combination rather than the drug alone. The most defensible position generally covers powder attributes, device operation, and delivered-dose performance together.

Combination products

Combining sumatriptan with a second migraine therapy may create a commercial opportunity. The strongest established example is sumatriptan plus naproxen, marketed as Treximet. Combination products can support method-of-use, composition, dosage, and pharmacokinetic claims, but they face complex obviousness, prior-art, and patent-term issues.

Potential combinations include:

• Sumatriptan plus naproxen.
• Sumatriptan plus antiemetic therapy.
• Sumatriptan plus a formulation that reduces gastric dependence.
• Sumatriptan with device-enabled rescue dosing.

A combination strategy must account for the decline of triptan use in some patients after the introduction of CGRP antagonists and ditans.

How strong is the current sumatriptan patent estate?

The core patent estate is weak because the molecule and early dosage forms are mature. The remaining strength is concentrated in narrow product claims.

Estate component	Strength	Reason
Sumatriptan compound	Low	Core rights expired
Standard immediate-release tablets	Low	Multiple generic suppliers and routine excipients
Standard injection	Low to moderate	Sterile manufacturing and device barriers remain, but formulation differentiation is limited
Standard nasal spray	Low to moderate	Generic and branded products compete; design-around is feasible
Nasal powder plus device	Moderate to high	Device integration and performance claims can create barriers
Taste-masked ODT	Moderate	Depends on clinical utility and non-obvious excipient architecture
Combination therapy	Moderate	Claims can be valuable but face prior-art and obviousness risks
Manufacturing process	Moderate	Stronger where scale-up, particle engineering, or sterility controls are difficult
Method of use	Low to moderate	Narrow claims may be vulnerable to label carve-outs and litigation

The commercial value of a patent is likely to exceed its legal breadth when the protected formulation is difficult to reproduce, requires a proprietary device, or is supported by clinical evidence. A broad claim to "a sumatriptan formulation comprising a pharmaceutically acceptable excipient" would have limited practical value.

Which companies are challenging or competing with sumatriptan products?

The competitive field includes generic manufacturers, branded delivery-system developers, and newer migraine drug companies.

Generic competition

Generic sumatriptan tablets are widely available from multiple applicants. The tablet market is highly price-sensitive and favors scale, reliable supply, low manufacturing cost, and pharmacy-channel access.

Nasal spray and injection markets have fewer technical suppliers because they require device qualification, sterile production, specialized filling, or bioequivalence strategies that may be more complex than tablet development.

Branded and differentiated competitors

Relevant branded or differentiated products have included:

• Imitrex, originally developed by Glaxo Wellcome and marketed by GlaxoSmithKline.
• Treximet, sumatriptan plus naproxen.
• Tosymra, a low-volume sumatriptan nasal spray.
• Onzetra Xsail, a breath-powered sumatriptan nasal powder product.
• Zecuity, an iontophoretic transdermal sumatriptan patch that was withdrawn from the U.S. market because of skin injury and burning concerns. [4]

The market also competes with other triptans, gepants such as ubrogepant and rimegepant, lasmiditan, ergot derivatives, nonprescription analgesics, and preventive CGRP therapies.

What is the FDA regulatory status of sumatriptan formulations?

Sumatriptan tablets, injection, and nasal spray have established FDA regulatory pathways. A conventional generic tablet typically proceeds under an ANDA. A materially different route, formulation, device, or clinical profile may require a 505(b)(2) application.

Regulatory pathway by opportunity

Product concept	Likely FDA pathway	Main regulatory burden
Conventional tablet generic	ANDA	Bioequivalence, CMC, labeling, inactive-ingredient acceptability
New ODT or oral film	ANDA or 505(b)(2)	Bioequivalence, taste, disintegration, stability
New nasal spray	ANDA or 505(b)(2)	Device performance, local tolerability, PK, spray characterization
Nasal powder with new device	505(b)(2) or NDA	Device-drug combination, clinical bridging, emitted dose
New injection device	ANDA or 505(b)(2)	Human factors, container closure, sterility, dose accuracy
Combination product	505(b)(2) or NDA	Combination safety, efficacy, interaction, labeling

FDA has published product-specific guidance for some sumatriptan dosage forms and generally evaluates bioequivalence using pharmacokinetic endpoints, clinical endpoint studies, or device-performance data depending on the product. [5]

For excipient strategy, the regulatory distinction is important. An inactive ingredient previously used in an approved route and dosage form has a lower regulatory risk than a novel excipient, a new route, or a substantially higher exposure. Nasal and injectable products receive particular scrutiny for local tolerability, impurities, microbial quality, and container compatibility.

What patent litigation and settlement risks affect sumatriptan?

The historical litigation profile centered on generic challenges to branded sumatriptan products and later disputes involving differentiated delivery systems. Paragraph IV risk is now greatest for later-developed formulation or device patents, not for the expired core compound.

Paragraph IV considerations

A generic applicant evaluating a listed sumatriptan product should assess:

• Whether the Orange Book patent is still unexpired.
• Whether the patent claims the formulation, device, method, or manufacturing process.
• Whether a section viii statement can omit a method-of-use claim.
• Whether the proposed label induces infringement.
• Whether the applicant can design around pH, excipient concentration, spray parameters, or device architecture.
• Whether a 30-month stay could delay approval following notice of a Paragraph IV certification.

Settlement agreements may include licenses, delayed entry dates, authorized generic arrangements, or restrictions on particular dosage forms. The Federal Trade Commission reviews certain pharmaceutical patent settlements for anticompetitive features. [6]

For a new excipient-based product, litigation risk is lower when the developer avoids listed claims and relies on a distinct device, concentration, process, or label. Risk increases when the product reproduces the commercial architecture of a branded nasal powder or combination product.

What commercial opportunities exist in sumatriptan excipients?

The most attractive opportunities are concentrated in products that improve onset, usability, or tolerability.

Opportunity ranking

Opportunity	Patient problem addressed	Commercial outlook
Taste-masked ODT or oral film	Nausea and difficulty swallowing	Moderate
Preservative-free nasal spray	Nasal sensitivity and excipient exposure	Moderate
Lower-volume nasal spray	Comfort and portability	Moderate to high
Mucoadhesive nasal formulation	Retention and absorption	Moderate, with tolerability risk
Breath-powered nasal powder	Rapid, non-oral delivery	High technical differentiation, higher device cost
Reduced-pain injection	Injection aversion	Moderate
Unit-dose rescue pack	Portability and adherence	Moderate
Sumatriptan-naproxen or other combination	Convenience and sustained relief	Moderate, but crowded
Pediatric-friendly formulation	Administration and taste	Moderate
Sustainable packaging and excipient reduction	Environmental and cost objectives	Low to moderate unless required by buyers

Revenue exposure

Generic tablet revenue is structurally exposed to price erosion because multiple suppliers can produce conventional products. Higher-value revenue is more defensible in:

• Branded nasal systems.
• Device-linked products.
• Combination products.
• Specialty pharmacy channels.
• Unit-dose and travel-oriented packaging.
• Products with clinical evidence for faster relief or improved tolerability.

The development case depends on whether the product can command a premium over low-cost tablets and whether payers recognize the value of avoiding oral administration. A technically superior formulation without a reimbursement or adherence advantage may not support a durable price premium.

How does sumatriptan compare with newer migraine medicines?

Sumatriptan remains relevant because of its low cost, long clinical history, and rapid injectable and nasal options. Newer gepants avoid vasoconstrictive triptan pharmacology and may be preferred for some patients with cardiovascular risk or triptan intolerance. They also have their own patent and pricing barriers.

Attribute	Sumatriptan	Gepants	Lasmiditan
Drug class	Triptan	CGRP receptor antagonist	5-HT1F agonist
Generic availability	Broad	Limited or absent for leading brands	Limited
Cost position	Low for tablets	Higher	Higher
Non-oral delivery	Injection, nasal	Primarily oral	Oral
Main formulation opportunity	Excipient and device differentiation	Lifecycle management and combinations	Oral formulation and safety positioning
Patent exposure	Core estate largely expired	Stronger active branded estates	Active product-specific estates
Commercial barrier	Generic price erosion	Payer access and patent duration	Sedation and driving restrictions

Sumatriptan’s best defense against newer therapies is a rapid, low-cost, route-diverse product portfolio. Excipient innovation must improve the practical treatment experience rather than merely alter composition.

What manufacturing and geographic barriers apply to sumatriptan products?

Conventional tablets have low manufacturing barriers. Nasal and sterile products have higher barriers because they require specialized equipment, validated filling operations, device assembly, and tighter container-closure controls.

Geographic coverage

The U.S. market is governed by FDA approvals, Orange Book listings, and U.S. patent rights. European and other markets require separate assessment of:

• National or regional marketing authorizations.
• Supplementary protection certificates.
• European Patent Convention validation.
• Local device requirements.
• Reference-product and generic bioequivalence rules.
• National reimbursement and substitution policies.

A formulation patent may have different remaining term and enforceability by country. Patent families should be mapped separately for the U.S., Europe, Japan, China, Canada, and major emerging markets.

Manufacturing barriers

The most material barriers include:

• Micronization and particle engineering for nasal powders.
• Moisture-controlled manufacturing and packaging.
• Spray-pump reproducibility.
• Sterile filling for injection products.
• Device-drug combination assembly.
• Extractables and leachables control.
• In-use stability and microbial integrity.
• Human-factors validation.
• Reliable supply of specialized excipients or coated particles.

These barriers can support licensing or contract-manufacturing opportunities even when the underlying sumatriptan patent estate is weak.

Key Takeaways

• Sumatriptan’s compound and conventional tablet exclusivity are largely expired.
• The commercial opportunity is in delivery systems, not the active ingredient.
• Nasal spray, nasal powder, ODT, oral film, injection-device, and combination products offer the strongest formulation-led strategies.
• Excipient patents are most valuable when tied to a defined technical effect, device, deposition profile, stability benefit, or clinical outcome.
• Standard tablet excipients provide low patent differentiation and face severe generic price erosion.
• Preservative-free nasal products, taste masking, lower-volume delivery, and breath-powered powder systems have the clearest commercial rationale.
• Biosimilar risk is not applicable because sumatriptan is a small molecule.
• Paragraph IV risk is now concentrated in product-specific formulation, device, and method-of-use patents.
• Zecuity demonstrates that non-oral delivery can fail commercially when local tolerability and device safety are inadequate.
• Any licensing strategy should prioritize proprietary device integration, manufacturing know-how, and clinically validated usability.

FAQs

Can a new sumatriptan excipient create market exclusivity?

Yes, but only where the excipient system supports a patentable formulation, process, device interaction, or clinically relevant performance advantage. A conventional excipient substitution alone is unlikely to provide durable exclusivity.

Is sumatriptan suitable for an orally disintegrating tablet?

Yes. An ODT could address nausea and swallowing difficulty, but taste masking, rapid dissolution, dose loading, and bioequivalence would determine commercial viability.

Which sumatriptan route offers the strongest formulation opportunity?

Nasal powder combined with a proprietary device offers the greatest technical differentiation. Nasal liquid spray has a lower development barrier but faces more direct competition and easier design-around.

Can a company launch a sumatriptan product without challenging every Orange Book patent?

Often yes. A developer may use a Paragraph IV certification, a section viii statement for method-of-use claims, or a distinct 505(b)(2) formulation strategy, depending on the listed claims and proposed labeling.

What is the main failure mode for a premium sumatriptan product?

The main failure mode is insufficient clinical or user value relative to inexpensive generic tablets. A more complex excipient system or device must produce faster relief, better tolerability, easier administration, or improved adherence that patients and payers will recognize.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
2. U.S. Food and Drug Administration. (2023). Sumatriptan succinate tablets prescribing information.
3. U.S. Food and Drug Administration. (2016). Onzetra Xsail approval letter and prescribing information.
4. U.S. Food and Drug Administration. (2016). FDA drug safety communication: Zecuity sumatriptan patch.
5. U.S. Food and Drug Administration. (2024). Product-specific guidance documents for generic drug development.
6. Federal Trade Commission. (2024). Agreement filings under the Medicare Prescription Drug, Improvement, and Modernization Act.